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Abstract
Patient knowledge and understanding of the therapy are an important factor 
in treatment success. Multiple factors were identified to cause a treatment failure 
such as side effects of the medications, rejection of the diagnosis by patients, lack 
of patient understanding about their medication, noncompliance, and the cost 
of medication. In addition, improvements in patient medication counseling and 
education may help in prevention of many adverse drug interactions, drug-drug or 
food-drug interactions, in turn enhancing medication adherence which depends 
basically on a patient’s acceptance of the information about the health threat itself. 
For these reasons, an evaluation of patients’ knowledge of medicine and its use may 
help screen for problems in therapy and improve therapeutic outcomes. The results 
of this evaluation may also be used to educate providers about areas of potential 
problems in which they may be able to influence change.
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1. Anticoagulation therapy
Coumarins have been used clinically since the 1950s and are likely the most 
widely studied medicines currently in clinical use [1, 2]. Anticoagulation therapy 
with warfarin has been a standard clinical practice to prevent ischemic stroke in 
patients associated with atrial fibrillation (AF) [3–6]. A meta-analysis demonstrates 
that adjusted-dose warfarin reduces stroke risk by 64% when compared to placebo, 
which is corresponding to an absolute annual risk reduction in all strokes of  
2.7%, while antiplatelet agents reduce stroke risk by 22% [7]. In the ACTIVE W 
trial, anticoagulation therapy had a relative risk reduction of all strokes by 40% 
when compared to the combination of clopidogrel and aspirin, with no difference 
in bleeding events between both treatments [8]. Furthermore, anticoagulants may 
reduce the risk of death rate in AF patients by 38% [9], so about 70–80% patients 
with AF are suitable for the long-term use of warfarin [10, 11].
However, it increases the risk for major bleeding. Clinical studies revealed that 
the risk of intracranial hemorrhage, the most common type of bleeding, is as great 
as that of thromboembolic events warfarin is used to prevent [12, 13].
Therefore, the optimal use of warfarin for atrial fibrillation requires precise 
assessment of established risk factors of bleeding, such as advanced age, hyperten-
sion, stroke, alcoholism, and malignancy [14]. In addition, rigorous reporting of 
Anticoagulation Drugs - The Current State of the Art
2
warfarin-associated bleeding is warranted, as patients who bleed often discontinue 
treatment, which put them at a higher risk of thromboembolism [15, 16].
1.1 Warfarin pharmacodynamics
Warfarin is a drug derived from 4-hydroxycoumarin group and acts by inhibit-
ing vitamin K epoxide reductase, an enzyme which recycles vitamin K into its 
reduced form (Figure 1). Reduced vitamin K is responsible for carboxylation of the 
specific blood clotting factors II (prothrombin), VII, IX, and X as well as anticoagu-
lant factor protein C and protein S [18–20]. Thus warfarin is not a direct antagonist 
of vitamin K but rather acts by depletion of reduced vitamin K in tissues.
As shown in Figure 2, inhibition of the reduction of vitamin K results in a reduc-
tion in the conversion of fibrinogen to fibrin which in turn reduces clot formation.
1.2 Warfarin pharmacokinetics
Warfarin is a racemic mixture of two optically active isomers, the R and S 
enantiomers [18]. Warfarin is highly water soluble and rapidly absorbed from the 
gastrointestinal tract and has high bioavailability [22, 23]. The bioavailability of 
warfarin is more than 95% [24, 25], and some reports had applied 100% bioavail-
ability when developing models [26, 27].
Warfarin reaches maximal blood concentrations about 1.5 hours after oral 
administration [22, 28]. The plasma half-life of racemic warfarin mixture is 
36–42 hours [29], and this means that it takes 5–7 days to reach steady state since 
warfarin is started or when the dosage is adjusted.
The antithrombotic effect of vitamin K anticoagulants has conventionally been 
attributed to their anticoagulant effect, which in turn is mediated by the reduc-
tion of the four vitamin K-dependent coagulation factors (II, VII, IX, and X). The 
vitamin K-dependent clotting factors have varying half-lives: 6 hours for factor VII, 
24 hours for factor IX, 36 hours for factor X, and 60–72 hours for factor II (pro-
thrombin). Thus, the anticoagulant effect (reduce coagulation of blood, prolonging 
the clotting time) develops in 2 days, whereas an antithrombotic effect (reduce 
formation of blood clots (thrombi)) of warfarin requires 6 days of treatment [30].
Numerous environmental factors such as drugs, diet, and various disease states 
were identified to affect warfarin by altering its kinetics and dynamics [31]. Drugs 
such as cholestyramine can reduce the absorption of warfarin, thus reducing its 
anticoagulant effect. R-warfarin is metabolized primarily by CYP1A2 and CYP3A4, 
while S-warfarin is metabolized primarily by CYP2C9 [32]. Potential warfarin drug 
interactions could occur with a concomitant administration of medicines that are 
metabolized by these P450s, and as a consequence, a number of metabolic medicine 
interactions have been reported for warfarin. For example, drugs such as cimeti-
dine, amiodarone, and omeprazole potentiate the anticoagulant effect of warfarin 
by inhibiting its metabolism, whereas some drugs like barbiturates, rifampin, 
azathioprine, and carbamazepine inhibit the anticoagulant effect by enhancing its 
clearance [33]. In addition, long-term alcohol consumption has a similar potential 
to increase the clearance of warfarin [34].
Aspirin [35] and nonsteroidal anti-inflammatory drugs (NSAIDs) increase the 
risk of warfarin-associated bleeding by inhibiting platelet function [36].
1.3 Dietary vitamin K
As the action of warfarin is modified by vitamin K, a variable dietary intake of 
vitamin K may alter the extent of the anticoagulation effect. An increased intake of 
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dietary vitamin K (foods high in vitamin K include leafy green vegetables (cooked 
and raw), broccoli, brussels sprouts, cabbage, pickled cucumber, asparagus, 
kiwifruit, okra, green beans, and salad greens like lettuce) or vitamin K-containing 
supplements will increase the production of functional coagulation factors depend-
ing on vitamin K which is sufficient to reduce the anticoagulant response to war-
farin [37]. Furthermore, patients with poor dietary intake of vitamin K often have 
a less stable control of anticoagulation [38]. It has been suggested to provide these 
Figure 2. 
Warfarin’s effects on the clotting cascade [21].
Figure 1. 
Mechanism of action of warfarin [17].
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unstable anticoagulated patients (with poor vitamin K intake) with oral vitamin 
K supplementation. However, unrecognized intake of such can lead to warfarin 
resistance [37].
The drug-grapefruit juice interaction enhances plasma concentration (Cmax) of 
orally concomitantly administered drugs. This interaction has been reported with 
40 pharmaceutical products, including the vitamin K antagonist [39]. Grapefruit 
can affect the metabolism of a variety of medications through the cytochrome 
P450 enzyme system located in the small intestine and liver. The enzymes that are 
affected are 3A4, 1A2, and 2A6. The (R) enantiomer of warfarin is metabolized 
by CYP1A2 and CYP3A4, which could contribute to this theoretical interaction of 
warfarin with grapefruit [40].
1.4 Warfarin monitoring
The relation between blood clotting and coumarin derivatives was established 
by Dam and Doisy who shared the Nobel Prize in 1943 for their work [41, 42]. 
Warfarin has a narrow therapeutic index in which effectiveness and safety are a 
tight balance between stroke risk and bleeding risk; hence, careful dose titration 
and monitoring are required.
The prothrombin time (PT) test is the most common test used to monitor vita-
min K anticoagulant therapy [43]. The normal prothrombin time is 12–14 seconds 
[44]. As PT monitoring of warfarin treatment is not standardized when expressed 
in seconds, a calibration model which was adopted in 1982 is now used to standard-
ize reporting by converting the PT ratio measured with the local thromboplastin 
into an international normalized ratio (INR) [45]. INR is calculated by raising the 
prothrombin time ratio (PT; the patient’s prothrombin time divided by a reference 
normal prothrombin time to the power of international sensitivity index (ISI)) as 
follows (Eq. (1)):
  INR =  ( Patient PT ___________________  Mean normal PT) 
ISI
 (1)
where ISI relates the sensitivity of a given thromboplastin (a tissue factor used 
as a reagent in PT test) to the sensitivity of the World Health Organization’s first 
primary international reference preparation of thromboplastin, which was assigned 
an ISI of 1.0 [46]. Each manufacturer assigns an ISI value for any tissue factor they 
manufacture which is usually between 1.0 and 2.0.
Instead of a specific value of the INR target, a therapeutic window is utilized as 
the recommended target range for specific diagnosis, e.g., in atrial fibrillation the 
clinical benefits of warfarin are highly dependent on maintaining the INR within 
the therapeutic range of between 2 and 3, while mechanical heart valve replacement 
often requires a slightly higher target range of INR (2.5–4.0) [47–50]. As shown in 
Figure 3, INRs below this range increase the risk of stroke, while INR values above 3 
or 4 are associated with increased bleeding rate [51].
Further quality assessment of the treatment involves calculation of time spent 
in the therapeutic range (TTR). In Rosendaal method, the difference between two 
consecutive INR readings, which was within the target range, was divided by the 
total difference between them [52].
1.5 Warfarin-related adverse drug events
The most common side effect from over-anticoagulation is bleeding from any 
anatomical site. There are many risk factors that increase the risk of hemorrhage 
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in patients on oral anticoagulant therapy, such as increasing age (≥60); previous 
stroke; comorbidities, i.e., diabetes mellitus; recent myocardial infarction; anemia 
(defined as hematocrit <30%); the presence of malignancy; concomitant; antiplate-
let usage; uncontrolled hypertension; liver/renal failure; and previous gastrointesti-
nal bleed [53].
The most feared hemorrhagic complication of anticoagulants is the intracranial 
hemorrhage (ICH) which accounts for approximately 90% of deaths from warfa-
rin-associated hemorrhage and for the majority of disability among survivors [54]. 
Nonetheless, ICH rates in clinical trials conducted in AF patients on oral anticoagu-
lant therapy are small, reported to be between 0.3 and 0.6% per year [55], and the 
absolute increase in major extracranial hemorrhages is even smaller, at ≤0.3% per 
year [56]. The risk of ICH associated with warfarin use was twice that of aspirin, 
but the absolute risk was small at 0.2% per year [7].
Other than hemorrhage, other important side effects of warfarin are acute 
thrombotic complications, such as skin necrosis and limb gangrene [57, 58].
2. Patients’ knowledge about warfarin therapy
2.1 Factors impacting patient’s knowledge about warfarin therapy
Evidence from the literatures suggests that patients’ knowledge about their 
warfarin therapy is generally poor with many demographic and clinical factors 
influencing their level of knowledge [2, 59–74].
IN the USA, a 52-item questionnaire related to the knowledge of warfarin was 
administered to 100 patients with atrial fibrillation in a face-to-face interview 
with a dietitian [69]. The survey questions were compiled based on five categories: 
general warfarin knowledge, compliance, drug interactions, herbal or vitamin 
interactions, and diet. For the total population, the average percentage of correct 
responses was 36%. The average score by category was 64% (general knowledge), 
71% (compliance), 17% (drug interactions), 7% (herbal or vitamin interactions), 
and 23% (diet). Results from the former study suggested that in general, patients 
on warfarin, especially those at highest risk of stroke, had a poor understanding of 
their medication.
In Germany, in a study aimed to investigate the patients’ knowledge on antico-
agulants and the patient characteristics associated with low knowledge, an 8-item 
multiple-choice test was developed and distributed to 59 anticoagulated medical 
Figure 3. 
Maintaining INR in the therapeutic range is crucial to prevent strokes and avoid bleeding [51].
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inpatients of a German university hospital [66]. The scoring range was 0–8 points 
(each correct answer giving 1 point). The average knowledge was 55% with the 
most often wrong answers about questions regarding drug-drug and drug-food 
interactions. The former study revealed no significant correlation between the total 
test score and any of the patient characteristics.
McCabe and colleagues [68] described the self-management knowledge and 
behaviors of patients with recently detected AF. One hundred subjects were inter-
viewed by telephone to assess knowledge after 2-week hospitalization. They found 
a knowledge deficit related to the purpose of medication and complications of 
warfarin. The knowledge deficits were greater in older subjects and in subjects with 
less formal education. The patients aged between 65 and 74 years had knowledge 
scores of 26.6 (out of a possible 50), as compared to 19.1 for those aged between 75 
and 94 years (P = 0.001); this may be due to cognition disorders. Despite knowl-
edge deficits among the patients, they were high adherent to taking medication and 
anticoagulation monitoring.
In England, a pilot study to examine patient’s knowledge and perceptions of AF 
and their anticoagulant treatment before and after a brief educational interven-
tion was conducted [67]. Thirty-three patients completed the baseline interview; 
by then, they were given an information booklet which explained about AF, 
treatment options and their benefits/risks, and what the INR is and what factors 
may affect it. They were reassessed to their knowledge and perceptions of AF in 
a follow-up assessment session. Out of 33 (35.5%) patients that completed the 
follow-up assessment, 52% were aware about anticoagulants preventing blood clots, 
which increased to 70% post-intervention. However, few patients were aware of 
the benefit of stroke prevention associated with anticoagulants. The intervention 
significantly improved patient’s knowledge of the target INR range and factors that 
may affect INR levels (P = 0.001 and P = 0.014, respectively); however, it had little 
effect on increasing awareness of the bleeding risks associated with anticoagulants.
To measure patient’s knowledge about warfarin and to identify factors related 
to higher level of knowledge, Hu et al. [64] conducted a telephone survey among 
100 patients with mitral valve replacement (MVR) using a validated 20-item 
questionnaire. They found that about 61% of participants had insufficient knowl-
edge of warfarin therapy (score ≤ 80%). Among all variables studied, age was 
negatively related to warfarin knowledge scores, while family incomes greater 
than US$25,000, education greater than grade 8, and being employed significantly 
related to higher warfarin knowledge scores (P < 0.05). However, gender and 
ethnicity were not related to warfarin knowledge scores.
Besides all literatures mentioned above, the knowledge of warfarin therapy was 
tested in a sample of 122 patients attending at the warfarin clinic using 9 questions 
with a maximum score of 1.0 [71]. They found the level of knowledge was generally 
poor with more obvious knowledge deficient about the possible consequences of 
under- or over-anticoagulation, drugs that might interact with warfarin, and man-
agement of a missed dose. In their study, they found that increasing age negatively 
impacts upon knowledge about warfarin therapy. The mean warfarin knowledge 
scores declined with advancing age; <65-year-olds scored 0.47; 65–74-year-olds 
scored 0.44; and >75-year-olds scored 0.39. Other sociodemographic factors such 
as lower family income, limited health literacy, unemployment status, and lower 
education levels appeared to negatively influence patients’ knowledge. However, 
they did find a weak but positive correlation between patients’ knowledge of warfa-
rin therapy and the number of INR values that were within the target range  
(Correlation coefficient r 0.20, P = 0.024).
Roche-Nagle et al. [2] evaluated the patient perception of anticoagulation risks, 
tablet recognition skills, and complications of warfarin therapy in 150 patients 
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attending the anticoagulation clinic. Majority of the patients (n = 125, 83%) were 
able to identify the 1 mg tablet correctly, 105 (70%) identified the 3 mg tablet, and 
98 (65%) identified the 5 mg tablet correctly. In addition, about 60% were aware 
about the potential complications from over- and underdosage with warfarin; 
however, only 33 (22%) were unaware that restrictions on alcohol use are required 
when taking warfarin. This study suggested that patient knowledge regarding 
anticoagulation therapy is not optimal, and consequently, a significant group may 
be at risk from serious complications because of this inadequate knowledge.
To investigate whether the knowledge and perceptions of antithrombotic 
therapy differ between ethnic groups in the UK, Nadar et al. [75] conducted a 
cross-sectional questionnaire survey among 180 patients attending anticoagulation 
clinic (135 white European, 29 Indo-Asian, and 16 Afro-Caribbean). The average 
knowledge score among all participants was 5.5 out of 9, with no significant dif-
ferences between all ethnic groups. However, this study highlighted the gaps in 
the knowledge of patients from ethnic minorities and suggested that these groups 
should receive a special attention in the provision of information. Moreover, they 
have identified age as a negative factor of warfarin knowledge with the lowest score 
among patients older than 61 years.
In a historical cohort with questionnaires to 242 patients discharged from 
hospital, identified from hospital pharmacy records as being prescribed warfarin 
frequency of testing and levels of INR within 6 months of discharge, the level of 
INR aimed at by GP, complication rates, and patient knowledge about anticoagula-
tion were measured [72]. Only 27% of all patients answered more than 8 out of 10 
questions correctly. In this study, higher education level was identified as a predic-
tor of high knowledge, but there was no relationship between the knowledge level 
and the INR control.
In Qatar, a cross-sectional survey using a 20-question questionnaire was deliv-
ered to 140 patients who were taking warfarin for at least 2 months [76]. Out of 
12 questions about warfarin knowledge, 10 questions were derived from the Oral 
Anticoagulation Knowledge (OAK) test that was developed by Zeolla et al. [77]. The 
OAK questions covered the topics on warfarin drug interaction; interpretation of 
INR value, food, and vitamin K; effect of missing a dose; and when to seek a medi-
cal attention. In this study, the satisfactory level was considered answering 10 out 
of 12 questions (≥75%). They found that 79 patients (56%) had a satisfactory level 
of knowledge. The lowest score was in the knowledge of management of missing a 
dose and drug-drug interaction.
Another study using the OAK test was conducted in Jordan among 117 patients 
using warfarin, who were selected randomly [78]. They found that the majority 
(64%) of respondents can distinguish between different strengths of warfarin 
tablets by color. However, a deficit in knowledge was obvious in the areas of vitamin 
K and drug interactions with warfarin, skipping dose management, and PT/INR 
test. It was suggested that including clinical pharmacist services in the anticoagula-
tion clinics may result in the improvement of patients’ knowledge toward warfarin 
use and PT/INR test.
In a study sought to determine the level of knowledge and to what extent 
patients adhere to OAC therapy, Van Damme et al. [79] developed a questionnaire 
comprising 10 multiple-choice questions, including 2 questions about each of the 5 
knowledge domains: (1) general information about the functioning of the medica-
tion, (2) possible side effects, (3) interactions with food, (4) drug interactions, 
and (5) lifestyle. For each question, four possible answers were given, one of which 
was correct. In this cross-sectional study which included 57 patients, the median 
total score on the knowledge questionnaire was 7 on a scale of 0–10 with only 9 
patients (15.7%) answering more than 8 questions correctly. They found that the 
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participants had moderate to poor knowledge regarding the kinds of medication 
that can be taken in case of headaches, the sports to be avoided, what to do when a 
dose of medication is missed, symptoms related to uncontrolled level of medication 
in the blood, the effect of alcohol in blood-thinning, and the influence of certain 
vitamins on the medications.
Finally, another study aimed to collect information on six items of anticoagu-
lation counseling (mode of action of warfarin, adverse effects of over or under 
anticoagulation, drugs to avoid, action if bleeding or bruising occurs, and alcohol 
consumption) from 70 consecutive patients on anticoagulant therapy [74]. They 
found that most patients reported are being clearly advised on five of the six items, 
but their knowledge about anticoagulation was generally poor. Few patients were 
able to correctly identify adverse conditions associated with poor control of antico-
agulation: bleeding was identified by only 30 (60%), and bruising by 23 (56%), and 
only 7 (14%) could identify 3 or more self-prescribed agents which may interfere 
with warfarin.
2.2 Relation of patients’ warfarin knowledge to their therapeutic outcomes
To date, there are important published literatures that highlight the level of 
patients’ knowledge about warfarin and its relation to the therapeutic outcome, as 
well as education strategies and their impact on therapy outcomes. In these litera-
tures, there is a general consensus that improved patient knowledge about warfarin 
therapy improving therapeutic outcomes [59, 66, 71, 80–82].
Kagansky et al. [80] have measured patient’s knowledge about warfarin by a 
warfarin knowledge-testing questionnaire. The questionnaire was submitted to 
elderly patients (n = 323) to assess their knowledge and impression on the quality of 
the relevant education that they received from the medical system on the following: 
risk of thromboembolic complications, prevention of thromboembolic complica-
tions by oral anticoagulation (OAC) therapy, the significance of OAC monitoring, 
and risk of bleeding. Among all participants, only 21.3% of the patients are satisfied 
about the education on OAC therapy that they received from the medical staff. In 
their study, patients with insufficient education on OAC therapy were more likely 
to increase major bleeding events (5.2 per 1000 patient-months) compared with 
no education (1.1 per 1000 patient-months). This study also showed that older 
patients with better knowledge about their warfarin therapy had 45% of their INR 
values within the therapeutic range than patients with poorer knowledge (35%); 
P < 0.001.
These findings were supported by another study [81] which reported that older 
patients (n = 125) who possessed a better understanding of warfarin therapy spent 
about 70% of the time within the therapeutic INR range than those with a poorer 
understanding (63%). The results of this latter study, however, were not statistically 
significant, reflecting the large amount of variability within each group and also 
possibly due to the limited number of patients included.
In Italy, Barcellona and colleagues [82] developed a questionnaire concentrated 
mainly on the patients’ understanding of why they were taking oral anticoagulants, 
the mechanism of the therapy through its regular assumption, dietary behavior 
(vegetable intake), current diseases that did not require hospitalization, interactions 
with other drugs, and assumption of other drugs. It was administered to a group 
of 219 consecutive anticoagulated patients attending the thrombosis center. The 
percentage time spent in the therapeutic range was calculated using the INR Day 
Program by Rosendaal et al. [52]. The difference in time spent in the range between 
patients who knew why they were taking the oral anticoagulant and those who did 
not was statistically significant only in the older group (89% vs. 76%, P = 0.04).
9Knowledge, Adherence, and Quality of Life among Warfarin Therapy Users
DOI: http://dx.doi.org/10.5772/intechopen.86371
In another study of Barcellona et al. [59], the time spent within the therapeutic 
range by patients taking oral anticoagulants was improved by two different, consec-
utive educational approaches on the crucial aspects of oral anticoagulant therapy. 
In this study, 240 patients were randomly allocated into three groups; a course that 
focused on the questions in the interview was given to the first group (n = 80); 
a brochure containing the correct answers to questions was given to the second 
(n = 81); nothing was provided for the third (n = 79). A significant difference was 
found in the TTR between the quarters preceding and following the interview with 
13% increase in the mean TTR among all groups.
Not all studies have found a positive correlation between patient knowledge and 
outcomes of warfarin therapy. In a sample of 52 patients, knowledge of warfarin 
therapy was assessed with an 18-question multiple-choice test and associated with 
anticoagulation control [62]. The anticoagulation control was defined as the num-
ber of blood tests in the appropriate therapeutic range divided by the number of 
blood tests performed during the 60-day period. This study showed no significant 
association between knowledge or education and the proportion of INRs within 
the therapeutic range. Moreover, insufficient education on OAC as perceived by 
the patient or caregiver was one of the significant predictive factors for bleeding 
complications (OR 8.83).
In Fang et al.’s [83] study, health literacy was measured using the bilingual 
short-form Test of Functional Health Literacy in Adults (s-TOFHLA), dichoto-
mized as “limited” (score 0–22) and “adequate” (score 23–36) among 179 anti-
coagulated English- or Spanish-speaking patients. INR control was assessed by 
calculating the time in therapeutic range for each patient using an adapted linear 
interpolation method [52], defined as the proportion of person-time within the 
target therapeutic range over the total person-time of follow-up. It was found 
that patients with limited health literacy were more likely to have incorrect 
answers to most questions addressing warfarin-related knowledge and numeracy 
with incorrect answers to questions about warfarin’s mechanism of action, side 
effects, medication interactions, and frequency of monitoring, after adjusting 
for age, sex, ethnicity, education, cognitive impairment, and years on warfarin. 
However, limited health literacy was not significantly associated with TTR over 
the previous 12 months.
In the USA, another study aimed to explore the association between literacy 
and numeracy skills among patients on warfarin, and their anticoagulation control 
was conducted among 143 patients older than 50 years attending 2 anticoagulation 
clinics [84]. They found that The INR variability was higher among patients with 
lower literacy (P = 0.009) and lower numeracy skills (P = 0.004). The time in the 
range was similar among patients at different literacy levels (P = 0.9); however, 
patients with lower numeracy level spent more time above their therapeutic range 
(P = 0.04) and had a trend of less time spent in range (P = 0.10).
In Malaysia, two previous studies have been conducted to assess the patients’ 
knowledge and relate their knowledge to INR control [85, 86]. Hasan et al. [85] 
assessed the anticoagulation knowledge and INR control among patients on warfa-
rin. In this cross-sectional study, 156 randomly sampled patients were interviewed 
using a validated interviewer-administered questionnaire, and all patients’ INR 
readings were recorded from 2008 to 2010. The authors found the average score of 
patients knowledge was 66.5% + 36.0% on how warfarin works, 42.9% + 44.9% for 
interaction between warfarin and alcohol, and 49.2% + 21.1% for adverse effects. 
Among all variable studied, they found a negative correlation between patients’ 
knowledge and age (P = 0.001, r = −0.293) and a positive correlation between 
patients’ knowledge and their education level (P = 0.001, r = 0.365). Furthermore, 
no significant correlation was found between patients’ INR control and their 
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knowledge on the mechanism of action of warfarin, the interaction between warfa-
rin and alcohol, and the side effects of warfarin.
Another cross-sectional survey was conducted at the Warfarin Clinic of Hospital 
Teluk Intan, Malaysia, and tended to determine the factors that correlated with 
the patient’s knowledge of warfarin therapy, the level of medication adherence, 
and INR control [86]. A total of 52 patients were interviewed with a mean ± SD 
age of 58.73 ± 9.55 years. Only 44.2% of patients knew about their medications, 
but the medication adherence was fairly good at 76.1%. The study showed that age, 
income level, level of education, and literacy in various languages were significantly 
associated with the patient’s knowledge on warfarin therapy (P < 0.05). The study 
did not find any association between anticoagulation and the level of knowledge 
of anticoagulation. However, the major limitation of the former two studies is the 
limited sample size used.
It is also important to highlight that some of the aforementioned studies, regard-
less of their results, are limited by the use of a non-validated warfarin knowledge-
testing instruments or questionnaire to evaluate patient knowledge [2, 66–69, 
73–75, 86]. Validation indicates that the questionnaire has been thoroughly tested 
for content validity, measures of question difficulty, readability, and item/person 
reliability. Only after a knowledge assessment instrument has been validated can 
sound scientific conclusions be drawn from its results [87]. The appropriate psycho-
metric methodology must be followed to ensure that an assessment measure is valid 
and reliable for testing the specific objectives or constructs. In theory, this process 
demonstrates that an instrument’s results are accurate, consistent, reproducible, 
and stable over time [87–89].
To date, only two questionnaires measuring patient knowledge of warfarin 
therapy have been validated: the Oral Anticoagulation Knowledge test, created and 
validated by Zeolla et al. [77], and the Anticoagulation Knowledge Assessment 
(AKA) questionnaire, designed and validated by Briggs et al. [90].
In Zeolla et al. [77], the Oral Anticoagulation Knowledge, a new instrument, 
was developed by four nationally recognized anticoagulation experts to ensure 
content validity. The test was administered to 72 subjects on warfarin and 27 
from a group of age-matched subjects not on warfarin to assess construct validity. 
Subgroups of warfarin subjects were retested approximately 2–3 months after initial 
testing to assess test-retest reliability. The OAK test was administered to 74 subjects 
taking warfarin and 27 age-matched subjects not on warfarin. In this study, subjects 
taking warfarin scored significantly higher than those not on warfarin (72% vs. 
52%, respectively; P < 0.001), supporting the construct validity of the instrument. 
Test-retest reliability was acceptable, with a Pearson’s correlation coefficient of 0.81, 
and the internal consistency reliability was 0.76. However, the association between 
the level of knowledge and clinical outcomes was not tested.
Another validated tool is the Anticoagulation Knowledge Assessment test, 
which was developed by Briggs et al. [90]. It is a 29-multiple-choice instrument that 
measures patient knowledge in 9 content areas, each worth 3.45 points. The validity 
of the instrument was assessed among 60 patients managed in two anticoagulation 
clinics who had received warfarin therapy for a mean of 28 months. The majority 
(80%) of patients who participated in the study had 12 or more years of education. 
The instrument was designed to be self-administered at a sixth grade reading level. 
Content validity of the instrument verified that the AKA instrument contains a 
variety of questions of varying levels of cognitive difficulty. However, the authors 
did not report whether they performed key reliability assessments (e.g., internal 
reliability or test-retest reliability); furthermore, they did not examine the relation-
ship between patient’s knowledge and the anticoagulation control.
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In literature, Baker et al. [91] used the validated AKA questionnaire. Correctly 
answering 21 questions (72.4%) or more was needed for the determination of 
adequate knowledge of anticoagulation therapy (passing score). Interestingly, this 
cross-sectional study showed that 74% (n = 185) of patients receiving long-term 
warfarin therapy had achieved a pass rate. Statistically, no significant correlation 
between warfarin knowledge and INR control was found. These results may have 
been inflated as the questionnaire is a self-completed questionnaire at home and 
there is a possibility of assistance from others.
On the other hand, the impact of educational program in reducing the clinical 
adverse event rates was tested by a randomized trial [92]. They reported a decrease 
in the adverse event rates by threefold less in the educated group compared to the 
control group. This supports the significant and independent impact of the educa-
tional program on the reduction in risk of events (OR 0.25, 95% CI 0.1–0.7).
Similarly, other studies showed that patient knowledge has a positive effect in 
the clinical outcomes with the highest rate of major bleeding events among patients 
who had poor knowledge about warfarin [80, 93]. In Beyth et al.’s [93] study, there 
was a reduction in hospitalizations among patients receiving structured warfarin 
education compared to those in a control group (3 vs. 9 hospitalizations, respec-
tively, out of a total of 12 hospitalizations; P = 0.08). Moreover, the time spent 
within the therapeutic range was higher in the educated group than in the control 
normal care group (56% vs. 32%; P < 0.001).
In summary, evidence from previous studies, such as Davis et al. [62] (n = 52), 
Fang et al. [83] (n = 139), Estrada et al. [84] (n = 143), Group TNAS [72] (n = 242), 
and Baker et al. [91] (n = 260) suggested no association between patients’ warfarin 
knowledge and anticoagulation control. Some of the results of these latter studies, 
however, cannot be generalized because of their use of small sample sizes [62], 
number of variables relating to patient knowledge measured [62], and use of non-
standardized data collection techniques [91].
The inverse relationship between the individual patient’s level of knowledge 
about warfarin and the rate of adverse outcome events has been reported in other 
literatures [2, 68, 71, 80, 92].
3. Health-related quality of life of warfarin users
The term health-related quality of life (HRQoL) has been used when the concern 
of researchers is to investigate the influence of the disease and treatment on the 
quality of life of the individual [94]. This narrower concept has been used to avoid 
ambiguity between the definition of quality of life in the common sense and that 
used in clinical and medical trials.
Warfarin use is challenging [18], since it has a narrow therapeutic index; it 
interacts with other drugs, alcohol, and food [31, 95]; and the clinical response to 
it is affected by many factors such as patients’ compliance and overall knowledge 
of therapy [74, 82]. Therefore, warfarin therapy requires a special care in order to 
control the desirable levels of blood coagulation and to prevent hemorrhagic and 
thromboembolic complications. Such care can lead to changes in the lifestyle of 
warfarin users since this involves changes in the dietary habits, the use of alcohol, 
and the performance of physical activity [96, 97], as well as the need to adhere 
strictly to the treatment regimen, the inconvenience of dosing adjustments, and 
the need for regular blood tests to monitor INR levels, together with the fear of 
complications such as the risk of minor or major bleeding and stroke [98]. All these 
changes caused by the use of anticoagulant treatment negatively affect the patient’s 
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HRQoL. Perceived reduction in HRQoL is an important factor, which may influence 
the physician’s prescription and patient’s use of warfarin therapy.
To study the HRQoL of OAC users, authors have used different types of instru-
ments. In a literature review regarding specific instruments available to evaluate 
the HRQoL of patients using OACs, the authors identified seven instruments [99]. 
In Brazil, a new specific instrument, the Duke Anticoagulation Satisfaction Scale 
(DASS), was developed by Samsa et al. [100] and recently validated by Pelegrino [101]. 
Some authors used a measurement of HRQoL obtained through the generic instru-
ment such as the Medical Outcomes Survey 36-item Short Form (SF-36) [96, 100, 102, 
103] and found that the more impaired HRQoL domains were physical aspects and 
vitality [96, 102], pain [100], physical functioning, and general health status [96].
In a cross-sectional study aimed to analyze the HRQoL and its relationship with 
gender, age, duration, and indication for the use of OAT, a total of 178 patients were 
interviewed, and the HRQoL was assessed through 8 domains of the SF-36 [104]. 
The means of the domains of the SF-36 ranged from 82 (social aspects) to 54.8 
(physical aspects). In their study, the men had higher scores than the women in the 
majority of the domains of the SF-36, except for general health status. However, 
these differences were only significant in the domains, mental health, and pain. 
Elderly patients diagnosed with atrial fibrillation and with less than 1 year of 
medication use presented a worse HRQoL evaluation.
The HRQoL was also evaluated through a cross-sectional study with a sample 
composed of 72 patients with atrial fibrillation and mechanical heart valve at the 
anticoagulation outpatient unit of the Federal University of Bahia’s University 
Hospital [105]. The patients were submitted to two quality of life evaluation ques-
tionnaires: SF-36 and DASS. The quality of life perception of the patients studied, 
based on both instruments, was positive regarding the treatment with OAC. The 
SF-36 presented an average score of 62.2 (±20.0). Among the SF-36 evaluated 
domains, the physical-emotional aspect was the most compromised one. The DASS 
presented an average score of 67.1 (±18.2), and the domain presenting a greater 
compromise was the one related to the treatment inconveniences. The authors 
identified many factors impacting patients’ HRQoL; previous hemorrhagic event, 
comorbidities, drug interactions with medicines that increase the anticoagulant 
effect, lower education level in the SF-36, and younger age group influence a more 
negative perception of the QoL, whereas lower education level in the DASS and the 
duration of treatment for more than 1 year offer a more positive perception.
In a randomized, controlled trial including 333 atrial fibrillation patients using 
warfarin for stroke prevention, the impact of the long-term use of warfarin in their 
quality of life was assessed [97]. The results for their trial showed no significant dif-
ferences between warfarin-treated and control patients on well-validated measures 
of functional status, well-being, and health perceptions. The mean score of health 
perceptions was 68.8 in the warfarin-treated group vs. 66.6 in the control group 
(scale of 0 to 100; 95% CI). In contrast, patients taking warfarin who had a bleed-
ing episode had a significant decrease in health perceptions (−11.9; 95% CI). The 
authors concluded that warfarin therapy is not usually associated with a significant 
decrease in perceived health, unless a bleeding episode has occurred.
In an attempt to find the strategies to improve the HRQoL of patients undergo-
ing anticoagulation therapy, a previous study found that patient self-management 
improves general treatment satisfaction and decreases patients’ perception 
of treatment-related daily hassles, distress, and strain on their social network 
(Gadisseur et al., 2004). This is supported by other researchers who noted an 
improvement in many of treatment-related areas of QoL through patient self-man-
agement in comparison with routine anticoagulant care through family physicians 
[106, 107, 108].
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4. Adherence toward warfarin
An assessment of warfarin adherence is important in improving patient’s 
warfarin-taking behavior and INR control. Nonadherence includes not only a cessa-
tion of medication therapy but also taking the medication other than as prescribed 
(i.e., under-adherence, over-adherence, or not taking the dose at the prescribed 
time). Most studies reported medication adherence as a percentage of doses taken 
out of those prescribed over a specific period of time. While there is no general 
consensus on what constitutes adherence or nonadherence.
Nonadherence to OAC medication is generally problematic in practice. In a 
cohort study in the USA, 1005 patients with AF and taking warfarin are included, 
and there was a 32% reduction (from 65 to 44%) in the number of patients taking 
warfarin after 30 months [109].
Poor patient adherence to the prescribed drug regimen is often cited as an 
explanation for out-of-range INR measurements [110]. Despite this, there is little 
rigorous evidence of the level of adherence to warfarin, particularly among a broad 
spectrum of patients and anticoagulation practices. One reason for the lack of data 
on adherence to warfarin is the difficulty in measuring adherence [111].
In a prospective study of warfarin adherence, both under-adherence and over-
adherence were measured among a sample of 145 patients at 3 anticoagulation clin-
ics. The mean percentage of nonadherent days was 21.8% as measured by electronic 
medication event monitoring system (MEMS) [112].
In Singapore, another cross-sectional survey aimed to validate a patient-
reported medication adherence measure, the MMAS-8, within a convenience 
sample of 151 patients taking warfarin [113]. It was found that respondents with 
higher MMAS-8 scores are more likely to have a higher percentage of INRs within 
the therapeutic range (P = 0.01), higher adherence to diet recommendations 
(P = 0.02), and less perceived difficulty in taking all medications (P < 0.001); they 
were also more likely to take warfarin at the same time every day (P < 0.001). This 
study showed that the 8-item MMAS has good validity and moderate reliability in 
patients taking warfarin.
In the International Normalized Ratio Adherence and Genetics (IN-RANGE) 
study of 111 adults taking warfarin, factors impacting patient adherence toward war-
farin were studied [114]. It was found that demographic factors like education and 
occupation and psychosocial factors (such as lower levels of mental health function-
ing and poor cognitive functioning) are associated with nonadherence. Specifically, 
nonadherence was greater among those with educational levels beyond high school 
and those currently employed (compared with those unemployed and retired).
In a literature review by Brown et al. [115], many factors associated with OAC 
adherence among patients with AF were summarized as disease- and drug-related; 
patient knowledge, beliefs, and abilities; health system-related; economics; patient-
physician relationship; and patient demographic, psychosocial, and personality 
traits.
In another review article that identified many factors associated with nonadher-
ence in older adults, Murray et al. [116] developed a conceptual model of general 
medication adherence to improve adherence, assist in adherence research, and 
facilitate the development of multidimensional adherence improvement interven-
tions. They concluded from an extensive literature search that older adults are at 
special risk due to the burden of multiple chronic diseases and age-related factors, 
such as cognitive impairment and other environmental and social factors.
To assess barriers to OAC medication use among patients with AF, a new ques-
tionnaire was developed by Ingelgård et al. [65]. The authors identified 41 barriers 
to warfarin use and classified them into 4 groups: patient medical characteristics, 
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healthcare system factors, patient capability, and patient preference. On the other 
hand, Cohen et al. [117] summarized the factors that affect adherence to anticoagu-
lation medication as factors related to disease (e.g., symptoms, long-term therapy, 
morbidities), drug (e.g., adverse events, duration, dose frequency and complex-
ity, polypharmacy, cost), patient (e.g., lack of support, lack of disease knowledge, 
concerns, difficulty comprehending instructions, inability to adhere to restrictions), 
follow-up (e.g., shortage of time, costs associated with INR monitoring, patient 
unwilling to repeat testing, delay in laboratory reporting), and health system (e.g., 
patient-doctor relationship, reimbursement, lack of proper facilities or experience to 
manage therapy).
Added to the previous literature, Arnsten et al. [118] found significant relation-
ships between various demographic characteristics and adherence. Noncompliance 
patients were more likely than warfarin-adherent patients to be younger (mean 
age 53.7 vs. 68.7 years), male, and nonwhite. Non-adherent patients were also 
more likely to report a lack of understanding or knowledge of the reason for taking 
warfarin and were also less likely to have a regular physician.
In Korea, a cross-sectional survey involving 204 patients aimed to identify 
factors affecting medication adherence and their relationships with anticoagulation 
control in Korean patients taking warfarin [119]. They found that 56 (27.5%) of 204 
respondents were adherent. Their results showed that knowledge about warfarin 
exerts significant influence on medication adherence; however, medication adher-
ence was not associated with good anticoagulation level as measured by INR.
The association between medication adherence and the clinical outcome of 
warfarin was also studied previously. In Davis et al. [62], adherence was found 
as one of the many factors that contribute to anticoagulation control. In this 
cross-sectional survey, the 4-item Morisky survey was used to assess self-reported 
adherence. The researchers found that adequate adherence was reported by 50% 
of patients and it was significantly associated with good anticoagulation control 
(P = 0.01) [120, 121].
In addition, this relationship between medication adherence and the clinical 
outcome of warfarin was also studied by Kimmel et al. [122]. In this prospective 
cohort study involving three coagulation clinics in Pennsylvania, 136 patients 
treated with warfarin for various indications (with a goal INR of 2–3), adherence 
to anticoagulation therapy was monitored using electronic MEMS medication 
bottle caps. The authors found patients who fail to adhere to warfarin therapy as 
prescribed are more likely to experience problems with anticoagulation control. 
Patients who missed >20% of bottle openings are two times more likely to have 
under-coagulation (adjusted OR 2.10). On the other hand, a significant effect on 
INR with over-adherence was also demonstrated; patients who had >10% extra pill 
bottle openings had a statistically significant increase in over-coagulation (adjusted 
OR 1.73). Furthermore, the authors estimated that poor patient adherence to 
medications is responsible for more than 53% of all hospital admissions.
In contrast, another cross-sectional study studied the relationship between 
adherence and other factors with the INR stability [123]. Among all patients, 90% 
(n = 156) had high and medium adherence, and 117 (75%) had INR stability up to 
50% and 39 (25%) ≥ 75%. It was found that factors like adherence, age, level of 
education, socioeconomic level, interaction with other drugs, comorbidities, and 
vitamin K intake did not influence INR stability. However, longer anticoagulation 
time and drug cost were the factors related to the anticoagulation stability.
In studies among patients with diagnoses other than AF and on anticoagulation 
therapy, other psychosocial factors associated with poorer adherence were identi-
fied. These factors include depressive symptoms, pessimism, and a perceived lack of 
social support [111, 124, 125].
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5. Factors impacting anticoagulation control
A retrospective cross-sectional study was conducted in community clinics in 
Israel aimed to assess the level of anticoagulation control achieved in patients with 
AF and to explore patient factors that influence the anticoagulation control [126]. 
The univariate and multivariate analyses were performed to explore the association 
of patient variables with anticoagulation control. They found that the mean TTR 
was 48.6% with about two-thirds of patients had poor anticoagulation control, as 
evidenced by TTR of <60%. Poor control was significantly associated with female 
sex, advancing age, and comorbid conditions. Heart failure was found to be an 
independent predictor of poor control (OR: 1.63).
A different cohort methodology was applied for assessing the likelihood of poor 
INR control among AF patients [127]. They used linear regression analysis to detect 
clinical factors associated with TTR and binary logistic regression to evaluate the 
predictive factors for different cut-off values of TTR. They explored various vari-
ables as independent predictors of poor TTR: female gender, age <50 years, ethnic 
minority status, smoking, more than two comorbidities, and being treated with a 
beta blocker, verapamil, or, inversely, amiodarone use.
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